Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
Fiche publication
Date publication
janvier 2023
Journal
Neurology(R) neuroimmunology & neuroinflammation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc
Tous les auteurs :
Farina A, Villagrán-García M, Ciano-Petersen NL, Vogrig A, Muñiz-Castrillo S, Taillandier L, Michaud M, Lefilliatre M, Wang A, Lepine Z, Picard G, Wucher V, Dhairi M, Fabien N, Goncalves D, Rogemond V, Joubert B, Honnorat J
Lien Pubmed
Résumé
To clinically characterize post-immune checkpoint inhibitor (ICI) Hu antibody (Ab) neurologic disorders, we analyzed Hu-Ab-positive patients with neurologic immune-related adverse events (n-irAEs) and compared them with patients with other n-irAEs, ICI-naive patients with Hu-Ab paraneoplastic neurologic syndromes (PNSs) identified in the same study center, and those with Hu-Ab n-irAEs reported elsewhere.
Mots clés
Humans, Male, Female, Immune Checkpoint Inhibitors, adverse effects, Drug-Related Side Effects and Adverse Reactions, Peripheral Nervous System, Antibodies, Antinuclear, Lung Neoplasms
Référence
Neurol Neuroimmunol Neuroinflamm. 2023 01;10(1):